Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII

BACKGROUND AND OBJECTIVE: Emicizumab is a monoclonal antibody that bridges activated coagulation factor IX and factor X to restore effective hemostasis in persons with hemophilia A. It is indicated for routine prophylaxis of bleeding episodes in persons with hemophilia A. The aim of the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonsson, Fredrik, Schmitt, Christophe, Petry, Claire, Mercier, Francois, Frey, Nicolas, Retout, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249270/
https://www.ncbi.nlm.nih.gov/pubmed/33709296
http://dx.doi.org/10.1007/s40262-021-01006-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249270/
https://www.ncbi.nlm.nih.gov/pubmed/33709296
http://dx.doi.org/10.1007/s40262-021-01006-0

Ejemplares similares